Drug Profile
Research programme: antibodies - LifeArc/TetraGenetics
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Tetragenetics
- Developer LifeArc; Tetragenetics
- Class Antibodies; Antihyperglycaemics
- Mechanism of Action Kv1.3 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Type-1 diabetes mellitus in USA (Parenteral)
- 13 Sep 2021 Tetragenetics has been acquired by Abcellera
- 12 Dec 2017 TetraGenetics and LifeArc enters into a collaboration for development of antibodies for Type-1 diabetes mellitus